Whole genome sequencing reveals potential targets for therapy in patients with refractory KRAS mutated metastatic colorectal cancer

BMC Medical Genomics

Volumn 7, Issue 1, 2014, Pages

  Shanmugam, Vijayalakshmi ^a   Ramanathan, Ramesh K ^a,b   Lavender, Nicole A ^a   Sinari, Shripad ^a   Chadha, Manpreet ^b   Liang, Winnie S ^a   Kurdoglu, Ahmet ^a   Izatt, Tyler ^a   Christoforides, Alexis ^a   Benson, Hollie ^a   Phillips, Lori ^a   Baker, Angela ^a   Murray, Christopher ^a   Hostetter, Galen ^c   Von Hoff, Daniel D ^a   Craig, David W ^a   Carpten, John D ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^b Virginia G Piper Cancer Center   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

KRAS mutations; Metastatic colorectal cancer; Whole genome sequencing

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGED; APC GENE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CARCINOGENESIS; CASE REPORT; DNA SEQUENCE; FEMALE; GENE FUNCTION; GENE MUTATION; GENE TRANSLOCATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; INPPL1 GENE; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; ONCOGENE K RAS; PIK3CA GENE; POINT MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TCF7L2 GENE; TUMOR GENE;

AGED; BLOTTING, WESTERN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; GENE SILENCING; GENETIC PREDISPOSITION TO DISEASE; GENOME, HUMAN; HCT116 CELLS; HEK293 CELLS; HUMANS; INDEL MUTATION; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORIC MONOESTER HYDROLASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA, SMALL INTERFERING; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 84903790104     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-7-36     Document Type: Article

References (54)

1. Cancer statistics, 2013. Siegel R, Naishadham D, Jemal A, CA: a cancer journal for clinicians 2013 63 11 30
2. Colorectal cancer. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N, Lancet 2010 375 1030 1047
3. Evolving treatment of advanced colon cancer. Segal NH, Saltz LB, Annu Rev Med 2009 60 207 219
4. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, Group CS, Lancet 2013 381 303 312
5. Genomic and epigenetic instability in colorectal cancer pathogenesis. Grady WM, Carethers JM, Gastroenterology 2008 135 1079 1099
6. Association of p53 mutations, microvessel density and neoangiogenesis in pairs of colorectal cancers and corresponding liver metastases. Kern A, Taubert H, Scheele J, Rudroff C, Mothes H, Kappler M, Bartel F, Richter KK, Int J Oncol 2002 21 243 249
7. Genetic alterations during colorectal-tumor development. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL, N Engl J Med 1988 319 525 532
8. TGF beta signaling in health and disease. Akhurst RJ, Nat Genet 2004 36 790 792 (Pubitemid 39014092)
9. The consensus coding sequences of human breast and colorectal cancers. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE, Science 2006 314 268 274 (Pubitemid 44571966)
10. The genomic landscapes of human breast and colorectal cancers. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, Nikolsky Y, Karchin R, Wilson PA, Kaminker JS, Zhang Z, Croshaw R, Willis J, Dawson D, Shipitsin M, Willson JK, Sukumar S, Polyak K, Park BH, Pethiyagoda CL, Pant PV, et al. Science 2007 318 1108 1113 (Pubitemid 350134889)
11. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, Pugh T, Verhaak RG, Stransky N, Boutin AT, Barretina J, Solit DB, Vakiani E, Shao W, Mishina Y, Warmuth M, Jimenez J, Chiang DY, Signoretti S, Kaelin WG, Spardy N, Hahn WC, Hoshida Y, Ogino S, et al. Nat Genet 2011 43 964 968
12. Personalized oncology through integrative high-throughput sequencing: a pilot study. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, Kalyana-Sundaram S, Sam L, Balbin OA, Quist MJ, Barrette T, Everett J, Siddiqui J, Kunju LP, Navone N, Araujo JC, Troncoso P, Logothetis CJ, Innis JW, Smith DC, Lao CD, Kim SY, Roberts JS, Gruber SB, Pienta KJ, Talpaz M, Chinnaiyan AM, Sci Transl Med 2011 3 111ra121
13. Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sanchez-Olle G, Aura C, Prudkin L, Landolfi S, Hernandez-Losa J, Vivancos A, Tabernero J, Mol Cancer Ther 2012 11 2062 2071
14. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. Craig DW, O'Shaughnessy JA, Kiefer JA, Aldrich J, Sinari S, Moses TM, Wong S, Dinh J, Christoforides A, Blum JL, Aitelli CL, Osborne CR, Izatt T, Kurdoglu A, Baker A, Koeman J, Barbacioru C, Sakarya O, De La Vega FM, Siddiqui A, Hoang L, Billings PR, Salhia B, Tolcher AW, Trent JM, Mousses S, Von Hoff D, Carpten JD, Mol Cancer Ther 2013 12 104 116
15. A pilot study using next-generation sequencing in advanced cancers: feasibility and challenges. Weiss GJ, Liang WS, Demeure MJ, Kiefer JA, Hostetter G, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Phillips L, Benson H, Reiman R, Baker A, Marsh V, Von Hoff DD, Carpten JD, Craig DW, PloS one 2013 8 76438
16. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D, PloS one 2012 7 43192
17. Paired tumor and normal whole genome sequencing of metastatic olfactory neuroblastoma. Weiss GJ, Liang WS, Izatt T, Arora S, Cherni I, Raju RN, Hostetter G, Kurdoglu A, Christoforides A, Sinari S, Baker AS, Metpally R, Tembe WD, Phillips L, Von Hoff DD, Craig DW, Carpten JD, PloS one 2012 7 37029
18. SolSNP-1.01. http://sourceforge.net/projects/solsnp/files/SolSNP-1.01/: SolSNP-1.01
19. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA, Genome Res 2010 20 1297 1303
20. The Bioperl toolkit: Perl modules for the life sciences. Stajich JE, Block D, Boulez K, Brenner SE, Chervitz SA, Dagdigian C, Fuellen G, Gilbert JG, Korf I, Lapp H, Lehvaslaiho H, Matsalla C, Mungall CJ, Osborne BI, Pocock MR, Schattner P, Senger M, Stein LD, Stupka E, Wilkinson MD, Birney E, Genome Res 2002 12 1611 1618 (Pubitemid 35175100)
21. The sequence alignment/map format and SAMtools. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, Genome Project Data Processing S, Bioinformatics 2009 25 2078 2079
22. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Kumar P, Henikoff S, Ng PC, Nat Protoc 2009 4 1073 1081
23. Circos: an information aesthetic for comparative genomics. Krzywinski M, Schein J, Birol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Marra MA, Genome Res 2009 19 1639 1645
24. High frequency of mutations of the PIK3CA gene in human cancers. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE, Science 2004 304 554 (Pubitemid 38541907)
25. PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity. Ma K, Cheung SM, Marshall AJ, Duronio V, Cell Signal 2008 20 684 694
26. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, Ciardiello F, Nat Rev Clin Oncol 2009 6 519 527
27. Identification of c-MYC as a target of the APC pathway. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW, Science 1998 281 1509 1512 (Pubitemid 28425575)
28. APC inhibits ERK pathway activation and cellular proliferation induced by RAS. Park KS, Jeon SH, Kim SE, Bahk YY, Holmen SL, Williams BO, Chung KC, Surh YJ, Choi KY, J Cell Sci 2006 119 819 827
29. Loss of Dpc4 expression in colonic adenocarcinomas correlates with the presence of metastatic disease. Maitra A, Molberg K, Albores-Saavedra J, Lindberg G, The American journal of pathology 2000 157 1105 1111
30. Smad4-mediated signaling inhibits intestinal neoplasia by inhibiting expression of beta-catenin. Freeman TJ, Smith JJ, Chen X, Washington MK, Roland JT, Means AL, Eschrich SA, Yeatman TJ, Deane NG, Beauchamp RD, Gastroenterology 2012 142 562 571
31. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, Day F, Li S, Tsui C, Lipton L, Desai J, Jones IT, McLaughlin S, Ward RL, Hawkins NJ, Ruszkiewicz AR, Moore J, Zhu HJ, Mariadason JM, Burgess AW, Busam D, Zhao Q, Strausberg RL, Gibbs P, Sieber OM, Cancer Res 2013 73 725 735
32. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Poincloux L, Durando X, Seitz JF, Thivat E, Bardou VJ, Giovannini MH, Parriaux D, Barriere N, Giovannini M, Delpero JR, Monges G, Surg Oncol 2009 18 357 365
33. Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study. Burwinkel B, Shanmugam KS, Hemminki K, Meindl A, Schmutzler RK, Sutter C, Wappenschmidt B, Kiechle M, Bartram CR, Frank B, BMC Cancer 2006 6 268
34. Frameshift mutations of Wnt pathway genes AXIN2 and TCF7L2 in gastric carcinomas with high microsatellite instability. Kim MS, Kim SS, Ahn CH, Yoo NJ, Lee SH, Hum Pathol 2009 40 58 64
35. A genome-wide RNAi screen for Wnt/beta-catenin pathway components identifies unexpected roles for TCF transcription factors in cancer. Tang W, Dodge M, Gundapaneni D, Michnoff C, Roth M, Lum L, Proc Natl Acad Sci U S A 2008 105 9697 9702 (Pubitemid 352031363)
36. Comprehensive molecular characterization of human colon and rectal cancer. Cancer Genome Atlas N, Nature 2012 487 330 337
37. T-cell factor 4 functions as a tumor suppressor whose disruption modulates colon cell proliferation and tumorigenesis. Angus-Hill ML, Elbert KM, Hidalgo J, Capecchi MR, Proc Natl Acad Sci U S A 2011 108 4914 4919
38. VEGFA gene locus (6p12) amplification identifies a small but highly aggressive subgroup of colorectal cancer [corrected] patients. Vlajnic T, Andreozzi MC, Schneider S, Tornillo L, Karamitopoulou E, Lugli A, Ruiz C, Zlobec I, Terracciano L, Mod Pathol 2011 24 1404 1412
39. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Ishii H, Yazawa T, Sato H, Suzuki T, Ikeda M, Hayashi Y, Takanashi Y, Kitamura H, Lung Cancer 2004 45 325 337 (Pubitemid 39037714)
40. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer. Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S, Stracci F, Tofanetti FR, Ferraldeschi M, Di Carlo L, Ragusa M, Daddi G, Tonato M, Lung Cancer 2004 46 77 85 (Pubitemid 39201386)
41. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T, Ichinose Y, Lung Cancer 2006 53 91 96 (Pubitemid 43831360)
42. Prognostic significance of the expression of vascular endothelial growth factors A, B, C, and D and their receptors R1, R2, and R3 in patients with nonsmall cell lung cancer. Carrillo de Santa Pau E, Arias FC, Caso Pelaez E, Munoz Molina GM, Sanchez Hernandez I, Muguruza Trueba I, Moreno Balsalobre R, Sacristan Lopez S, Gomez Pinillos A, del Val Toledo Lobo M, Cancer 2009 115 1701 1712
43. Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Frederick L, Wang XY, Eley G, James CD, Cancer Res 2000 60 1383 1387 (Pubitemid 30152011)
44. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE, Meyerson M, Science 2004 304 1497 1500 (Pubitemid 38720929)
45. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M, Varmus H, Proc Natl Acad Sci U S A 2004 101 13306 13311 (Pubitemid 39209661)
46. Status of PI3K inhibition and biomarker development in cancer therapeutics. Markman B, Atzori F, Perez-Garcia J, Tabernero J, Baselga J, Ann Oncol 2010 21 683 691
47. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Vivanco I, Sawyers CL, Nat Rev Cancer 2002 2 489 501 (Pubitemid 37328931)
48. Phosphatidylinositol (3,4,5)P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3,4)P2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. Scheid MP, Huber M, Damen JE, Hughes M, Kang V, Neilsen P, Prestwich GD, Krystal G, Duronio V, The Journal of biological chemistry 2002 277 9027 9035 (Pubitemid 34952976)
49. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Franke TF, Kaplan DR, Cantley LC, Toker A, Science 1997 275 665 668 (Pubitemid 27061333)
50. A specific product of phosphatidylinositol 3-kinase directly activates the protein kinase Akt through its pleckstrin homology domain. Klippel A, Kavanaugh WM, Pot D, Williams LT, Mol Cell Biol 1997 17 338 344 (Pubitemid 26425623)
51. Impact of transgenic overexpression of SH2-containing inositol 5′-phosphatase 2 on glucose metabolism and insulin signaling in mice. Kagawa S, Soeda Y, Ishihara H, Oya T, Sasahara M, Yaguchi S, Oshita R, Wada T, Tsuneki H, Sasaoka T, Endocrinology 2008 149 642 650 (Pubitemid 351159340)
52. Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Prasad NK, Tandon M, Badve S, Snyder PW, Nakshatri H, Carcinogenesis 2008 29 25 34 (Pubitemid 351201738)
53. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, Stratton MR, Futreal PA, Nucleic Acids Res 2011 39 945 950
54. Therapeutic potential of SH2 domain-containing inositol-5′- phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer. Fuhler GM, Brooks R, Toms B, Iyer S, Gengo EA, Park MY, Gumbleton M, Viernes DR, Chisholm JD, Kerr WG, Mol Med 2012 18 65 75